Influenza clinical trials
44 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
- Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- BPL-1357 Against H1N1 Influenza Virus Challenge
- Influenza Immunization in Adults Over Age 75
- A Study to Learn About mRNA Vaccines Against Influenza in Adults
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
- Systems Investigation of Vaccine Responses in Aging and Frailty
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
- Dime La VerDAD: Verify, Debunk, and Disseminate
- Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2
- Flu Infection at UPHS
- Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
- COVID-19 Coagulopathy Extension Study
- Respiratory Virus Sampling and Repository
- Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
- Preparedness Through Respiratory Virus Epidemiology and Community Engagement
- Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India
- Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
- Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
- Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
- Influenza Human Challenge Model
- A/Texas Flu Challenge
- The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
- Study of Immune Responses to Influenza Vaccination
- H5N1 Milk Detection Study
- pH1N1 Blinded Challenge Study
- Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
- Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
- Characterizing the Human Airway Immune Response to FluMist Vaccination
- Immune Defense Protein Impact On Respiratory Immune Outcomes
- The Effects of Endotracheal Suctioning on Pain and Serum Markers
- Personalized Ventilator Settings for Patients on ECMO
- H1ssF Flu Vaccine Clinical Trial
- Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
- Evaluating Modes of Influenza Transmission 2b Baseline SAR
- Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge
- SAVE: School Ambassadors for Vaccine Education
- Patient-Centered Practical Vaccine Talk For Busy Clinicians
- A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
- Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
- Tfh Dysfunction in HIV and Aging
- B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Influenza” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.